cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cognition Therapeutics Inc
1 own
3 watching
Current Price
$1.96
$0.02
(1.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
53.44M
52-Week High
52-Week High
3.49000
52-Week Low
52-Week Low
0.90000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization53.44M
icon52-Week High3.49000
icon52-Week Low0.90000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Cognition Therapeutics Inc do?
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer s disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Read More
How much money does Cognition Therapeutics Inc make?
News & Events about Cognition Therapeutics Inc.
Globe Newswire
10 months ago
NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimers disease. The University of ...
Globe Newswire
1 year ago
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimers Disease, Dementia with Lewy Bodies and Geographic AtrophyNEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that a review ...
Globe Newswire
1 year ago
PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.(Nasdaq: CGTX) (the Company or Cognition) has released its fourth Conversations video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, ...
Globe Newswire
1 year ago
- CEO Participating on Panel Hosted by Alzheimers Drug Discovery Foundation -NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of ...
Globe Newswire
1 year ago
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating ...
Frequently Asked Questions
Frequently Asked Questions
What is Cognition Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cognition Therapeutics Inc shares?
plus_minus_icon
How can I buy Cognition Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cognition Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cognition Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cognition Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cognition Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cognition Therapeutics Inc?
plus_minus_icon
What percentage is Cognition Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cognition Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.96
$0.02
(1.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00